References

Unresolved reference

2024 · External reference

Alopecia Associated with the Use of Semaglutide and Tirzepatide: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS) from 2022 to 2023

10.1111/jdv.20197 · 2025 · External reference

Glucagon‐Like Peptide‐1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study

10.1016/j.jaad.2025.01.046 · 2025 · External reference

Risk of Hair Loss With Semaglutide for Weight Loss

2025 · External reference

GLP‐1 Agonists May Modulate Treatment Efficacy in Central Centrifugal Cicatricial Alopecia

10.1016/j.jaad.2025.04.058 · 2025 · External reference

A Closer Look at the Dermatological Profile of GLP‐1 Agonists

10.3390/diseases13050127 · 2025 · External reference

Alopecia and Semaglutide: Connecting the Dots for Patient Safety

10.1111/jocd.70125 · 2025 · External reference

Commonly Prescribed Medications Associated With Alopecia

10.1016/j.jaad.2017.01.060 · 2023 · External reference

GLP‐1 Agonists and Hair Loss: A Call for Further Investigation

10.1111/ijd.17246 · 2024 · External reference

Reversal of Alopecia by Insulin Therapy in Uncontrolled Type 2 DM: A Case Report

10.4103/jod.jod_66_21 · 2021 · External reference

The Rise of ‘Ozempic Face’: Analyzing Trends and Treatment Challenges Associated With Rapid Facial Weight Loss Induced by GLP‐1 Agonists

10.1016/j.bjps.2024.07.051 · 2024 · External reference

Treatment of Insulin Resistance With Tirzepatide Leading to Improvement of Hair Loss

10.1016/j.jdcr.2024.06.001 · 2024 · External reference

Tirzepatide Once Weekly for the Treatment of Obesity

10.1056/nejmoa2206038 · 2022 · External reference

Prescription Fills for Semaglutide Products by Payment Method

10.1001/jamahealthforum.2024.2026 · 2024 · External reference